Breakthrough in Ulcerative Colitis Treatment Using Live Bacterial Therapeutics

Strategic Insights -

Research conducted by a team at Central South University of Forestry and Technology has made significant strides in developing a novel approach to treating ulcerative colitis (UC) using live bacterial therapeutics (LBT). Despite the promise of LBT, several challenges have hindered their effectiveness, including low bacterial survival rates under harsh gastrointestinal conditions and difficulties in achieving long-term colonization. To address these issues, the researchers integrated genetic and chemical engineering to produce a polyelectrolyte composite coating that enhances bacterial survival in the gastrointestinal tract. This innovative strategy also utilizes controlled chemical modifications to improve bacterial resistance and employ bactericidal agents to dynamically modulate the intestinal microecology.

Key Takeaways:

  • A novel approach integrates genetic and chemical engineering to enhance the effectiveness of live bacterial therapeutics in treating ulcerative colitis.
  • The strategy employs bacterial programmability and gene editing to produce bactericidal agents that dynamically modulate the intestinal microecology.
  • A polyelectrolyte composite coating was developed, which increased bacterial survival in the gastrointestinal tract by 40-fold in the stomach and 74-fold in the small intestine.
  • Escherichia coli Nissle 1917 (EcN) was engineered to overproduce iron-carrier microcins (MccM) with a "Trojan horse" mechanism to target and disrupt pathogenic bacteria.
  • In a dextran sulfate sodium (DSS)-induced mouse UC model, EcN::mcmA@P/O treatment effectively reduced inflammation and improved intestinal flora regulation, presenting a promising and potentially safer long-term solution for UC.
  • Funders for this research include the Science and Technology Innovation Program of Hunan Province, Guangzhou Science and Technology Plan Project, National Natural Science Foundation of China (NSFC), and others.
  • The study has been peer-reviewed and published in "Advanced Materials."

Statistics:

  • The new approach increases bacterial survival in the gastrointestinal tract by 40-fold in the stomach and 74-fold in the small intestine.
  • The engineered EcN::mcmA strain was found to overproduce iron-carrier microcins (MccM) with a "Trojan horse" mechanism to target and disrupt pathogenic bacteria.
  • In a dextran sulfate sodium (DSS)-induced mouse UC model, the treatment effectively reduced inflammation by [insert statistical information, if available].
  • The new therapy presents a promising and potentially safer long-term solution for UC.

Sources:

  • "Synergistic Genetic and Chemical Engineering of Probiotics for Enhanced Intestinal Microbiota Regulation and Ulcerative Colitis Treatment" by Jiangtao Li et al., published in "Advanced Materials," 2025.
  • Central South University of Forestry and Technology, College of Food Science and Engineering, Natl Engn Res Ctr Rice & Byproduct Deep Proc, Changsha 410004, People's Republic of China.
  • Advanced Materials, 2025, Wiley-Blackwell, www.wiley.com/.